Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9806123 | 0.91 | CYP1A2 (0.60) | CYP1A2CYP2C9ALDH1A1MAPK1POLB | |
| SCHEMBL4988129 | 0.90 | CYP1A2 (0.56) | CYP1A2CYP2C9ALDH1A1MAPK1MEN1 | |
| SCHEMBL6233308 | 0.89 | CYP1A2 (0.55) | CYP1A2CYP2C9ALDH1A1MAPK1POLB | |
| SCHEMBL3459786 | 0.89 | CYP1A2 (0.65) | CYP1A2CYP2C9ALDH1A1MAPK1POLB | |
| SCHEMBL9436866 | 0.87 | CYP1A2 (0.59) | CYP1A2CYP2C9ALDH1A1MAPK1POLB | |
| SCHEMBL10752281 | 0.86 | CYP1A2 (0.58) | CYP1A2CYP2C9ALDH1A1MAPK1KDM4E | |
| P-Xylene SCHEMBL3752326 | 0.86 | CYP1A2 (0.70) | CYP1A2CYP2C9ALDH1A1MAPK1POLB | |
| SCHEMBL335423 | 0.85 | CYP1A2 (0.63) | CYP1A2CYP2C9ALDH1A1KDM4EHPGD | |
| SCHEMBL5484470 | 0.85 | CYP1A2 (0.63) | CYP1A2CYP2C9ALDH1A1POLBTSHR | |
| SCHEMBL31278334 | 0.85 | CYP1A2 (0.59) | CYP1A2CYP2C9ALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078124-A1 | METHODS OF PREPARING ERGOLINE ANALOGS | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025119223-A1 | METHOD FOR SYNTHESIZING AMANITIN AND DERIVATIVE THEREOF | 上海皓元生物医药科技有限公司 | 2025-06-12 | — | — | WO | claimed |
| US-11827608-B2 | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-28 | — | — | US | claimed |
| EP-4241083-A1 | DERIVATIZATION OF AT LEAST ONE ANALYTE OF INTEREST FOR MASS SPEC MEASUREMENTS IN PATIENT SAMPLES | F. Hoffmann-La Roche AG (CH) | 2023-09-13 | — | — | EP | claimed |
| US-20230273217-A1 | DERIVATIZATION OF AT LEAST ONE ANALYTE OF INTEREST FOR MASS SPEC MEASUREMENTS IN PATIENT SAMPLES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-08-31 | — | — | US | claimed |
| US-11718576-B2 | Compositions and methods comprising resveratrol | BIOCOGENT, LLC (US) | 2023-08-08 | — | — | US | claimed |
| US-20220267838-A1 | Sensitive and Accurate Genome-wide Profiling of RNA Structure In Vivo | THE PENN STATE RESEARCH FOUNDATION | 2022-08-25 | — | — | US | claimed |
| US-20220234984-A1 | COMPOSITIONS AND METHODS COMPRISING RESVERATROL | BIOCOGENT, LLC | 2022-07-28 | — | — | US | claimed |
| US-20220220081-A1 | METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | claimed |
| WO-2022096329-A1 | DERIVATIZATION OF AT LEAST ONE ANALYTE OF INTEREST FOR MASS SPEC MEASUREMENTS IN PATIENT SAMPLES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-12 | — | — | WO | claimed |
| EP-1247096-B1 | METHOD FOR IMMOBILISATION OF (AN) AFFINITY REAGENT(S) ON A HYDROPHOBIC SOLID PHASE | BIO RAD PASTEUR (FR) | 2005-03-30 | — | — | EP | claimed |
| US-20050032144-A1 | Method for selective conjugation of analytes to enzymes without unwanted enzyme-enzyme cross-linking | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-10 | — | — | US | claimed |
| US-20040115192-A1 | Ligand-targeted emulsions carrying bioactive agents | LANZA GREGORY M (US) | 2004-06-17 | — | — | US | claimed |
| US-20040052797-A1 | Method for immobilisation of (an) affinity reagent(s) on a hydrophobic solid phase | BIO-RAD EUROPE GMBH (CH) | 2004-03-18 | — | — | US | claimed |
| US-6676963-B1 | PROVIDE PROLONGED ASSOCIATION AND INCREASED CONTACT WITH LIPID BILAYER OF SPECIFIED TISSUES OR CELLS | BARNES-JEWISH HOSPITAL | 2004-01-13 | — | — | US | claimed |
| WO-2003043978-A2 | METHOD FOR SELECTIVE CONJUGATION OF ANALYTES TO ENZYMES WITHOUT UNWANTED ENZYME-ENZYME CROSS-LINKING | UNIVERSITY AND COMMUNITY COLLEGE SYSTEM OF NEVADA ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2003-05-30 | — | — | WO | claimed |
| US-5401634-A | Stable biologically active fluorochemical emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-28 | — | — | US | claimed |
| US-4794083-A | WITH CARBODIMIDE ON A POLYMER WITH AMINO OR CARBOXY FUNCTJONAL GROUPS | REANAL FINOMVEGYSZERGYAR (HU) | 1988-12-27 | — | — | US | claimed |
| US-4614723-A | Porphyrin derivatives as fluorescent markers for immunoassays | HOFFMANN-LA ROCHE INC. (US) | 1986-09-30 | — | — | US | claimed |
| US-4593004-A | Activating with carbodiimide compound | REANAL FINOMVEGYSZERGYAR (HU) | 1986-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220081-A1 | METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, MC2R | CYP1A2 541/4885CYP2C9 700/4885ALDH1A1 2431/4885 |
| US-11827608-B2 | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | CYP1A2 541/4885CYP2C9 700/4885ALDH1A1 2431/4885 |
| US-20260078124-A1 | METHODS OF PREPARING ERGOLINE ANALOGS | HTR1A, HTR2A, HTR7 | CYP1A2 732/4885CYP2C9 3685/4885ALDH1A1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.